Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?

@inproceedings{Funda2019OptimalTD,
  title={Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?},
  author={David P Funda and Lenka Palov{\'a}-Jel{\'i}nkov{\'a} and Jaroslav Goli{\'a}{\vs} and Zuzana Kroul{\'i}kov{\'a} and Alena Fajstova and Tom{\'a}{\vs} Hudcovic and Radek {\vS}p{\'i}{\vs}ek},
  booktitle={Front. Immunol.},
  year={2019}
}
Tolerogenic dendritic cells (tolDCs) are explored as a promising standalone or combination therapy in type 1 diabetes (T1D). The therapeutic application of tolDCs, including in human trials, has been tested also in other autoimmune diseases, however, T1D displays some unique features. In addition, unlike in several disease-induced animal models of autoimmune diseases, the prevalent animal model for T1D, the NOD mouse, develops diabetes spontaneously. This review compares evidence of various… CONTINUE READING

Figures and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 142 REFERENCES

OCILRP2 signaling synergizes with LPS to induce the maturation and differentiation of murine dendritic cells.

  • Biochemical and biophysical research communications
  • 2014
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…